Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Ripple Science Partners with Lakeside Life Science to Accelerate the Clinical Validation Process for Medsential’s Point-of-Care COVID-19 Antibody Test


Ripple Science Logo

Ripple Science Logo

I love that Ripple is making this highly involved and complex clinical process easier and streamlined.

Ripple Science today announced their partnership with Lakeside Life Science, a diagnostic research organization that is performing a clinical study to determine antibodies using Medsential’s COVID-19 IgG/IGM Rapid Test Cassette. With 11.6 Million cases and over 500,000 deaths worldwide, the public health crisis that is COVID-19 has accelerated organizations to adopt technology like Ripple, which shorten time-to-market for biopharma solutions.

Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts, leading to valuable time and cost savings. Medsential’s test is already available for high-complexity CLIA certified labs. Lakeside’s study will be validating the test in a clinical setting. Paul Allard, COO of Lakeside Life Science, explained how Ripple helps with a very short timeline: “Ripple is streamlining the whole clinical study process for us. Our timeline for this study is incredibly short. Normally we need four to six months for study start up and 18 months to enroll patients. Our goal is to complete this entire study under a month and a half.”

Allard anticipates a follow-on study to determine how long a person has the antibodies. Lakeside, an expert in testing validation, has confirmed that Medsential’s IgM/IgG antibody test outperform antibody tests from well-known industry healthcare providers. Allard said, “In moving to a long-term study, we want high confidence in our antibody testing solution and are delighted at Medsential’s results and how easy the tests are to use.”

Lakeside is using Ripple to quickly recruit and track patients from small, underserved community centers that don’t have access to standard testing or the tools to manage clinical studies. Patients from these small centers can benefit from access to testing and are more representative of the general population.

Clinical studies are known for their complex nature beginning with recruiting patients to continual patient engagement, especially for follow-up months after the study commences. Chiao-ih Hui, COO for Medsential, is pleased that many of the study complexities are being removed. “I love that Ripple is making this highly involved and complex clinical process easier and streamlined. This will accelerate and provide a model for getting our solution to point-of-care settings and to vulnerable populations who have the most need for these solutions.”

President and CEO of Ripple Science, Peter Falzon commented, “With COVID-19, the way we conduct clinical trials has changed and there is a heightened sense of urgency. The team at Ripple Science is dedicated to enabling clinical research teams to work remotely and adopt virtual research methods, while boosting recruitment and retention.”

About Lakeside Life Science:

Lakeside Life Science was founded in January of 2015, by W. Jeffrey and Paul Allard to bring patients and communities together to advance personalized medicine through the research and development of novel diagnostic tests. Lakeside provides the resources for their clients to bring their assays from invention to FDA clearance/approval, while putting patient needs first.

About Medsential:

Medsential LLC is a US FDA registered company that develops, manufactures, and distributes a broad range of medical products to customers. Established in 2005, Medsential is an ISO certified medical device company with the capabilities to manufacture and assemble a broad range of products. Medsential has an extensive distribution channel, salesforce, engineering platform, and production team to bring quality products to global markets.

About Ripple Science: Ripple Science accelerates clinical research with its secure, HIPAA-compliant suite of tools. By adapting sales and marketing automation to the process of patient recruitment, Ripple helps our customers recruit more participants, faster and reduces patients lost to follow-up. Ripple Science’s flagship product, Ripple, is currently being used by research investigators at more than 100 academic and research centers around the world, including Johns Hopkins University, Pennsylvania State University, University of California Los Angeles, the Brain Research Foundation Canada, University of East Anglia (UK), Cognito Therapeutics (Boston, MA) and the University of Michigan.

To learn more, please visit: https://www.ripplescience.com

Share article on social media or email:

ChronWell Launches Remote Physiologic Monitoring (RPM) Services for Gastrointestinal Physicians and Patients


News Image

“Specialists need better ways to get closer to patients, especially in these times of isolation. With RPM, we can expand our specialty protocols to better manage complex conditions like IBD without inconveniencing patients.” -Joe Rubinsztain, MD, CEO of ChronWell

ChronWell, a technology-enabled remote care management company, today announced the addition of its Remote Physiologic Monitoring (RPM) services. The goal of the new program is to closely monitor progress and improve patient adherence to treatment plans, reduce complications and help practices deliver better care while optimizing costs.

ChronWell RPM services will initially focus on patients with IBS (irritable bowel syndrome) and IBD (inflammatory bowel disease). Through digital collection tools, including wearable monitoring devices, mobile apps, secure messaging, and surveys, ChronWell’s RPM services will monitor patient health data, assess their chronic condition(s) and offer providers the ability to adjust treatment plans. Health data can include weight change, stool frequency and characteristics, appetite, fever or other indicators for change in disease and symptom progression.

“Specialists need better ways to get closer to patients, especially in these times of isolation,” said Joe Rubinsztain, MD, CEO of ChronWell. “With RPM, we can expand our specialty protocols to better manage complex conditions like IBD without inconveniencing patients.”

When using RPM to monitor patients outside the practice, providers can more appropriately assess risk and decide which patients benefit most from conservative measures or more aggressive interventions, leading to better outcomes, lower system cost and higher patient satisfaction.

ChronWell’s RPM services are part of a comprehensive care management program that also includes Chronic Care Management (CCM), Principal Care Management (PCM) and Transition Care Management (TCM) services.

To learn more about ChronWell’s Care Management program and RPM services, please visit http://www.chronwell.com/care-coordination/products/.

About ChronWell

ChronWell improves outcomes and reduces the cost of healthcare by partnering with leading specialty practices to deliver remote care management services. ChronWell is redefining how value-based care is delivered to patients suffering from chronic conditions by pairing highly skilled care teams with advanced technologies to improve patients’ lives beyond the walls of medical practice. For more information, follow us on LinkedIn or visit http://www.chronwell.com.

Share article on social media or email:

DuPont Nutrition & Biosciences Introduces CHOOZIT® BC 02 to Help Pizza Cheese Makers Expand Their Business


News Image

“As demand rises across the global pizza industry, pizza cheese makers have looked for solutions to make substantial improvement on the quality and consistency of their product,” said Annie Mornet, global product manager, Cheese Cultures at DuPont Nutrition & Biosciences.

DuPont Nutrition & Biosciences (DuPont) today announced the launch of CHOOZIT® BC 02, a new phage alternative for cheese makers looking to meet the increasing global demand for pizza cheese and meet consumers’ preference in terms of pizza cheese browning.

Part of the DuPont™ Danisco® portfolio of ingredients, the new culture joins CHOOZIT® BC 01 as a proprietary formulation designed to assist cheese makers to create added value and flexibility for their food service customers: enabling them to achieve a consistent quality pizza cheese in a wide range of ovens around the world, day after day.

The CHOOZIT® BC cultures offer key advantages, including robust processing conditions, browning control, better flexibility for pizza baking in oven conveyors, consistent cheese quality with no change in texture before shredding and a lower risk of spoilage – all in a natural, label friendly solution.

The cultures are clean label solutions to control browning, unlike many alternatives on the market that are formulated with additives. CHOOZIT® BC helps pizza cheese makers meet consumer preferences for natural products, while using less water in production, a lower volume of whey and less energy for whey drying.

Pizza cheese makers had long struggled to achieve consumers’ preferred cheese browning color using natural solutions, until last year’s successful roll-out of CHOOZIT® BC 01 in the European market. To date, CHOOZIT® BC 01 is in commercial use by a significant number of leading pizza cheese producers and in approval phases in key countries around the broader European region. These countries represent roughly 77% of the total pizza cheese produced in Europe(1).

“As demand rises across the global pizza industry, pizza cheese makers have looked for solutions to make substantial improvement on the quality and consistency of their product,” said Annie Mornet, global product manager, Cheese Cultures at DuPont Nutrition & Biosciences. “We introduced CHOOZIT® BC 01 last year and found that customers are very pleased with its unique performance. Pizza cheese makers have confirmed that CHOOZIT® BC 01 gives much better browning control for the same cheese quality, and for some particular pizza cheese manufacturing processes manufacturers have been able to use 25% less water in the pizza cheese process.”

“CHOOZIT® BC 02 takes it a step further,” she continued. “with CHOOZIT® BC 02 we present an even stronger offering to cheese producers who need to produce in industrial volumes. The cultures have been designed to provide the right acidification kinetics and proteolytic features to manage the yield and mineralization of the cheese. The metabolism of the different species allows for a better consumption of the sugars, especially galactose, throughout the process. Moreover, CHOOZIT® BC 01 and 02 are a biodiverse and alternative formulation leading to a higher robustness and limiting the phages issues.”

(1) DuPont Internal Data.

About DuPont™ Danisco®

DuPont™ Danisco® is the brand for a range of products that help provide enhanced bioprotection, an improved nutritional profile, and better taste and texture with greater cost efficiency and lower environmental impact, meeting the needs of manufacturers of food and beverages and dietary supplements. Through the work of the global network of food scientists and technologists in DuPont, the Danisco® range is supported by a uniquely broad spectrum of know-how across applications and processing.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com or http://www.biosciences.dupont.com

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at http://www.dupont.com/.

# # #

07/09/20

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

For further information contact:

Francis Stalder                    

+31-6 30 96 58 52                    

Francis.Stalder@dupont.com

Mariah Saerndahl                    

+1 715 210 2509

Mariah.Saerndahl@dupont.com

Share article on social media or email:

Puffy’s New Hybrid Mattress Range With Coils is Designed for Perfect Sleep


Puffy Royal Hybrid Mattress

Puffy Royal Hybrid Mattress

Our mattress range is evolving to cater to the varying comfort and support needs of our customers. Delivering the most innovative bedroom solutions in the industry is paramount to us.

America’s most comfortable mattress brand, has just announced the launch of an all-new hybrid mattress collection, designed with a combination of premium memory foam and encased contour-adapt coils for unmatched stability and support.

Puffy’s Hybrid Mattress range includes two comfort options: Puffy Lux Hybrid and Puffy Royal Hybrid. The company’s move into the Hybrid Mattress category strengthens its commitment to provide the most comprehensive sleep solutions in the industry.

“Our mattress range is evolving to cater to the varying comfort and support needs of our customers. Delivering the most innovative bedroom solutions in the industry is paramount to us. We’re excited about the addition of the Hybrid Mattress range and look forward to helping more people achieve better sleep than ever,” said Puffy CEO Arthur Andreasyan.

Contour-Adapt Coil Technology

The Puffy Hybrid Mattress range features the company’s uniquely luxurious cooling cloud memory foam, and an all-new innovative foam-encased coil base layer. The specialized contour-adapt coils offer greater responsiveness and stability. When combined with plush memory foam, the mattress softens to adapt to the body’s curves for a bespoke comfort feel.

Key Benefits of the Puffy Hybrid Mattress Range

By uniting the body-conforming properties of luxurious memory and the adaptive nature of innerspring coils, the product development teams at Puffy have innovated a hybrid mattress that truly encapsulates modern comfort.

Adaptive Contouring – an innerspring coil system constructed with contour-adapting properties acts as a natural reflex. The coils help the mattress to conform to each movement of the body. The coil base of Puffy Hybrid Mattresses delivers variable support that is highly customized in areas of high and low compression.

Enhanced edge support – the contour-adapt coil base is encased in high-density memory foam. The encasement protects the coils and creates stability from the center to the edge of the mattress. The foam acts as a shell on the base layer increasing the surface area of the mattress by 15% when sleepers sit or lay close to the edge.

Radically better motion isolation – breakthrough motion isolation technology drastically diminishes motion transfer for uninterrupted sleep.

Choice of plush comfort – customers can choose between the medium-plush luxurious comfort of the Puffy Lux Hybrid and the ultra-plush zoned comfort of the Puffy Royal Hybrid.

“We’ve curated a design that perfects the synergy between the sleep-inducing benefits of memory foam and adaptive support of coils. The innovation behind our hybrid mattress sets out to guarantee that every body shape, weight, and sleeping position will get supportive and rejuvenating rest,” he continued.

100% Made in the USA

Local sourcing and mattress manufacturing remain a standout value at Puffy. Exactly like every mattress in the range, the new Puffy Hybrid Mattress collection is 100% made in the United States. Everything – from ideation to technology, testing, materials, and construction – is all done locally.

A Complete Comfort System

Puffy’s Hybrid Mattress collection is the latest comfort innovation to join the rapidly growing company’s complete sleep system range. Other recent releases include the Puffy Blanket – a heavenly ultra-soft faux fur invention, and the temperature regulating Puffy Body Pillow.

“Each time we release a new comfort product, it’s a step closer to creating an integrated luxurious sleep experience like no other. It’s our mission to help people feel the life-changing benefits of healthy sleep. We have more amazing comfort to come, stay tuned,” said Puffy CEO Arthur Andreasyan.

The Puffy Hybrid Mattress collection is available now. Explore the benefits of the 4 layer, medium-plush Puffy Lux Hybrid or the 5 layers, ultra-plush Puffy Royal at https://puffy.com/pages/puffy-hybrid-mattress.

About Puffy

Puffy is a global mattress company currently operating in the United States, Canada, and the United Kingdom. The Puffy team is committed to developing total bedroom solutions to help customers achieve optimal sleep health. The company was founded on the idea of creating mattresses and bedroom products that feel like sleeping on a cloud.

Puffy has been featured on The Talk and was recently awarded Best Mattress of 2020. Puffy sells all products direct-to-consumers online. For more information, visit https://puffy.com.

Share article on social media or email:

ZipPrime and Lanmer Announce Product Commercialisation Agreement to Distribute ZipPrime’s SARS-CoV-2 Sampling and Detection Products and Lanmer’s PPE Supplies


Under the agreement, Lanmer will distribute ZipPrime’s SARS-CoV-2 compatible Viral Sample Transport Solution, Viral Nucleic Acid Isolation Kit, Quick Extraction Kit and RT-PCR SARS-CoV-2 Detection Kit in Europe, with a focus on the Baltic States. In addition, the companies will collaborate in the worldwide distribution of PPE and other COVID-19 relevant solutions sourced by Lanmer.

ZipPrime’s Viral Sample Transport Solution is available in both bulk and collection kit formats (with optional swab) and already has customers worldwide, via ZipPrime OÜ’s Turkish partner company Zip Prime Biyoteknoloji LTD. ŞTİ. (“ZipPrime Turkey”) – its developer and manufacturer. ZipPrime Turkey has additionally developed a Viral Nucleic Acid Isolation Kit, Quick Extraction Kit and RT-PCR SARS-CoV-2 Detection Kit which will also be distributed under the agreement. ZipPrime’s SARS-CoV-2 sampling and detection products offer equal or superior performance relative to the leading products on the market with competitive pricing.

Lanmer is capable of sourcing regulatory-approved Personal Protection Equipment and other COVID-19 related medical and research solutions with short lead and delivery times, for delivery worldwide, including products otherwise hard to obtain.

About ZipPrime OÜ:

Founded in 2013 and incorporated in Estonia in 2019, ZipPrime OÜ, together with partner company ZipPrime Turkey, founded 2008, develops and markets in vitro diagnostic and next-generation sequencing related technologies. ZipPrime has recently applied its DNA & RNA sample-handing know-how and technologies from the cancer liquid biopsy sector to the current COVID-19 pandemic to develop a range of superior products for SARS-CoV-2 sampling and detection. For more information about the company and its products and technology visit http://www.zipprime.com.

About Lanmer OÜ:

Founded in 2014, Lanmer OÜ offers medical and research solutions and clinical research monitoring services to clients in the Baltics and Nordics. For more information about the company and its products and technology visit http://www.lanmer.eu/en

Please direct PPE enquires to Kent Langel: kent.langel@lanmer.eu and SARS-CoV-2 sampling and detection product enquires to Neil Thomas: neil.thomas@zipprime.com

Share article on social media or email:

Kaplan and OnlineMedEd Announce Strategic Partnership to Empower Medical Students


This joining of forces combines Kaplan’s industry-leading test preparation question bank (Qbank) with an innovative multi-modality medical learning platform by OnlineMedEd that is currently being incorporated into the curriculum and teaching methodology of dozens of medical schools.

Healthcare professionals have always been a precious resource, perhaps now more than ever, and many more will be needed to address the health challenges of the future. To meet this need, Kaplan and OnlineMedEd are pleased to announce that they are entering into a strategic partnership with the goal of combining their respective strengths to help more students get through the rigors of medical school and start serving their communities.

This joining of forces combines Kaplan’s industry-leading test preparation question bank (Qbank) with an innovative multi-modality medical learning platform by OnlineMedEd that is currently being incorporated into the curriculum and teaching methodology of dozens of medical schools. This best-of-all-worlds study toolset will empower medical students throughout their education and give them an advantage on their USMLE® exams, the set of licensing exams necessary to pass before practicing medicine.

“When Kaplan revamped their already impressive qbanks, it was clear to us that they were the best option for students requiring a robust qbank in the months before the exam,” said Dustyn Williams, OnlineMedEd’s Lead Educator. “A partnership that paired our strengths made sense. By being able to leverage our PACE learning methodology which incorporates written materials and video lectures alongside ways to challenge and reinforce during the learning acquisition phase, with Kaplan’s robust test prep questions, students are going to have more depth in their knowledge and be better prepared for their exams.”

“Question practice is an incredibly effective technique, and we’ve recently overhauled our question bank resources to maximize learning outcomes,” said Phil Teelander, executive director, medical programs, Kaplan. “We know that medical students rely on a variety of components to accelerate their education, leveraging several providers based on their strengths. We’re excited to pair our new assessment assets with the engaging lectures and written materials that students really appreciate from OnlineMedEd. We’re coupling two effective resources to maximize student study time and improve student performance.”

Starting today, whenever a student purchases an annual subscription to OnlineMedEd’s Premium curriculum, they will also automatically receive a Partner Promo Code worth $129 to be applied towards Kaplan’s newly revamped qbank for board preparation.

An annual subscription to OnlineMedEd’s premium content includes their comprehensive slate of instructional videos, all ad-free, as well as the ability to access and download audio files, lecture notes, whiteboard graphics, flashcards, clinical cases, and more. More than 200,000 unique learners currently leverage the platform each month for clinical education and the company has recently invested millions of dollars and tens of thousands of hours into building the world’s most robust and unique basic sciences curriculum.

Kaplan qbanks have recently received substantial updates, including a complete revision of all questions, explanations, and simulated exams; hundreds of brand new questions; a brand new mobile app; enhanced answer explanations including 3D images, links to videos, and step-by-step strategy overviews; and an updated interface identical to the test.

By connecting Kaplan’s formidable test preparation tools with OnlineMedEd’s comprehensive slate of learning acquisition offerings, more medical students have a chance to excel as they progress through medical school and become the life-saving doctors the world needs.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Kaplan.

About OnlineMedEd

OnlineMedEd is a digital medical education firm whose mission is to change how medical education is approached, delivered by medical schools and learned by medical students. With approximately 200,000 learners on the site every month and used by 80% of third-and fourth-year medical students in 191 countries, the OnlineMedEd clinical education platform is built around its proven four-step process that includes access to more than 400 pages of notes with diagrams, tables, tips and insight into topics (prime), over 70 hours of organized, high-yield content to prepare medical students for boards and clinical rotations (acquire), 1,200 board-style clinical vignettes that can be taken by topic or mix and match to prepare for the test (challenge) and 10,000+ flashcards to review and reinforce the most essential, high yield information (enforce). The peer-reviewed content is developed by physician educators and delivered in a way that makes learning faster, easier and more reliable by focusing only on content medical students must learn and providing the tools to improve retention, which frees them to spend their time using what they’ve learned to practice actual medicine. For more information, visit http://www.onlinemeded.org.

About Kaplan

Kaplan, Inc. serves over one million students globally each year through its array of higher education, test preparation, professional education, English-language training, and university preparation programs, and offerings to individuals, institutions, and businesses. Across its 80-plus year history, first as a small test-prep pioneer and then an early online education leader and now a global education provider, Kaplan has been recognized for expanding educational access and using technology and learning science innovations to continually improve outcomes for its students and partners. Kaplan has operations in nearly 30 countries, employs more than 12,000 full- and part-time professionals, and maintains relationships and partnerships with more than 1,000 school districts, colleges, and universities, and about 10,000 corporations and businesses. Kaplan is a subsidiary of Graham Holdings Company and its largest division. For more information, please visit http://www.kaplan.com.

PRESS CONTACT

To arrange an interview, please contact:

OnlineMedEd:

Cam Wilson, JDI

617.997.9715

cam@jones-dilworth.com

Kaplan:

Russell Schaffer

917.822.8190

russell.schaffer@kaplan.com

Share article on social media or email:

Harmony Healthcare Sets the Record Straight on PPP Funding


The company withdrew its application after determining that it was ineligible to receive PPP funding due to industry size standards set by the SBA

Harmony Healthcare, the Tampa, Florida-based leader in non-clinical healthcare consulting and human capital management, received notification today that it was wrongfully included on the Small Business Administration’s (SBA) list of organizations with active Paycheck Protection Program (PPP) loans. The organization has not received any such funds.

Senior leadership is reaching out to the SBA to remove the organization from the list. The company respectfully requests media outlets to remove it from any published lists.

Share article on social media or email:

View article via:


Pdf

Print

The Sigourney Award Honors Four Recipients with Distinguished Independent Prize For Advancing Psychoanalysis and Psychoanalytic Thought


“The work of these award recipients represents Mary Sigourney’s vision of how psychoanalysis can serve humanity worldwide,” says Dr. William A. Myerson, PhD, MBA, co-trustee of The Sigourney Trust.

The Sigourney Trust has presented its highly prestigious Sigourney Award 2019 to four remarkable recipients in the international psychoanalytic community. While the formal spring 2020 presentation in Vienna was cancelled due to COVID-19 travel restrictions, the recipients are being personally congratulated and honored with a substantial cash prize and award for work completed.

“We continue to be impressed by the quality of work being put forth by our international applicants and congratulate this year’s award recipients,” says Dr. William A. Myerson, PhD, MBA, co-trustee of The Sigourney Trust. “We are proud to maintain Mary Sigourney’s original intent to reward innovative work and hope this distinctive acknowledgement continues to inspire those embracing psychoanalysis – both seasoned and emerging in experience – to apply from around the world for reward and recognition,” he adds.

The 2019 winners join a long list of the world’s top talent who, since 1990, have been honored with The Sigourney Award. The Award honors recipients’ recent past work, not future work, as judges look for a substantial body of outstanding work during the last ten years. A nominee’s accomplishments should be insightful or ground-breaking, advance the understanding or evolution of psychoanalysis and psychoanalytic thought, and advance the public good.

Recipients of The Sigourney Award – 2019:

Dr. Rodolfo Moguillansky‘s work has played a pivotal role in developing and expanding psychoanalysis in Argentina and throughout Latin America. While serving as rector of the Instituto Universitario De Salud Mental de APdeBA (IUSAM), Dr. Moguillansky helped lead efforts to attain full academic accreditation for the university’s psychoanalytic training program. Built on the International Psychoanalytic Association’s tripartite training model, the University’s fully accredited program has helped solidify psychoanalysis’ position as a legitimate area of study in Latin America and has attracted students from across South America.

A not-for-profit charitable organization based in Germany, Partners in Confronting Collective Atrocities (PCCA) is unique in its location of pain and guilt within the group, rather than in the individual. While PCCA is a community-based psychoanalytic and social welfare enterprise led by psychanalysts from various countries, it also attracts and recruits many non-analysts. PCCA seeks to positively impact the residual effects of trauma and atrocities on individuals, communities, and national groups. PCCA represents the extension and application of psychoanalysis to the sphere of social reality and offers a fruitful way of dealing with large scale trauma, beginning with the Holocaust and extending to other atrocities, victims, and perpetrators.

Work by Siri Gullestad, PhD, has profoundly impacted the evolution and acceptance of psychoanalysis as a scientific discipline in Norway. A researcher, theoretician, educator and a powerful public voice, Gullestad developed a highly innovative psychoanalytic theory that was applied to both university training and clinical treatment. A well-respected spokesperson for psychoanalysis, she is skillful at communicating the relevance of unconscious conflict and fantasy to the general public.

Dr. Henri Parens’ innovative research work in the United States has focused on a psychoanalytic approach to the understanding and treatment of aggression. Working with caregiver/children dyads, Dr. Parens and his colleagues documented their hypothesis that caregivers could be taught optimal ways to handle the emergence of aggression in children and this approach could improve the children’s lives. Dr. Parens and his colleagues used real life moments to help teach parents and caregivers how to respond in ways that would enhance their children’s emotional development. Focusing on the caregiver’s role in shaping the child’s capacity to manage their own aggression and teaching care givers new ways of responding at moments of real urgency between caregiver and child, Dr. Parens is able to teach new and alternative ways to handle aggression.

“The work of these award recipients represents Mary Sigourney’s vision of how psychoanalysis can serve humanity worldwide,” said Dr. Myerson. “Today, psychoanalysis embraces a range of philosophies, modern clinical theories, social advocacy, culture, art, and research. The Sigourney Trust honors the expansion and connection of psychoanalysis to many fields of study and experience through The Sigourney Award,” he added.

Applications for The Sigourney Award 2020 are being accepted through Sept. 15, 2020. Visit http://www.sigourneyaward.org for information and find The Sigourney Award on social platforms including Facebook and LinkedIn @SigourneyAward.

About The Sigourney Award

Established by Mary Sigourney in 1989, The Sigourney Award offers independent, international recognition and a substantial cash prize for outstanding work that advances psychoanalysis and psychoanalytic thought. Ms. Sigourney was a psychotherapist, publisher, and community activist who had a passionate interest in psychoanalysis and understood its ability to benefit and extend human conversation across various disciplines. To date, 129 Award Recipients from 21 countries represent her global vision. The Sigourney Award recipients’ ground-breaking work has significantly contributed to human affairs on topics ranging from neuroscience to feminism.

Share article on social media or email:

MagMutual introduces new commercial auto policy for healthcare sector


“One of our core precepts is to deliver the best product, and our new commercial auto option is part of that promise.”

MagMutual, one of the nation’s leading healthcare liability insurance providers, announced today that it will be launching a commercial auto product. The new offering is part of MagMutual’s business of medicine product suite, which also includes management liability, businessowners, workers’ compensation and commercial umbrella liability coverage.

“We strive to make sure we offer our PolicyOwners protection for all the potential risk exposures they face in the practice, business and regulation of medicine,” said Joe Wilson, MD, executive chairman of MagMutual. “One of our core precepts is to deliver the best product, and our new commercial auto option is part of that promise.”

MagMutual’s commercial auto policy will include industry-leading loss-control and joint claims-handling services provided through a partnership with RLI Transportation, a division of RLI Insurance Company. RLI has been at the forefront of specialty insurance coverage for more than 50 years and their Transportation division offers extensive experience and resources to support MagMutual commercial auto policyholders.

“MagMutual is one of the country’s top healthcare liability insurers, and our PolicyOwners count on us to deliver superior insurance solutions,” noted Neil Morrell, CEO and president, MagMutual. “We are confident RLI Transportation will help us give our PolicyOwners the same exceptional level of care and expertise that they’ve come to expect from MagMutual.”

More information about MagMutual’s commercial auto coverage option will be available on the company’s website, MagMutual.com, and through its sales representatives and insurance brokers later this month. Contact your agent or MagMutual company representative to learn more.

About MagMutual

For nearly four decades, MagMutual has been a leading provider of medical professional liability insurance. Today, we deliver comprehensive coverage for the practice, business and regulation of medicine to over 30,000 physicians and healthcare organizations nationwide. Our focus on innovation enables us to provide exceptional service, extensive support and financial benefits that result in improved outcomes and stronger PolicyOwners™. For more information, visit MagMutual.com.

Media contact:

Ed Lynch, EVP, MagMutual

elynch@magmutual.com, 404-842-5536

Share article on social media or email:

MLM Medical Labs Begins Global Expansion Through Acquisition of CirQuest Labs in Memphis, Tennessee, USA


MLM Medical Labs (“MLM”), a Great Point Partners (“GPP”) portfolio company, a specialty central lab based in Germany, today announced it has acquired Memphis, Tennessee based CirQuest Labs (“CirQuest”) as part of its global expansion strategy. With the acquisition of CirQuest, MLM has expanded to the United States and will be able to better serve the needs of its global clients. CirQuest is an industry leader in specialized laboratory services for the drug development industry. CirQuest provides specialized assay development, biomarker testing, and central lab services to its global client base of leading pharmaceutical and life sciences companies.

“CirQuest has an excellent reputation in the centralized lab industry with a core focus on scientific excellence and customized service. A combination with MLM will allow us to better serve our combined customer base through a globally integrated platform,” said Dr. Stephan Wnendt, MLM CEO.

“CirQuest provides key services to many of the world’s leading drug developers. MLM’s acquisition of CirQuest will create a global and nimble central lab platform serving the global clinical trial market,” said Rohan Saikia, Managing Director at GPP.

Dr. Lisa Jennings, Founder and CEO of CirQuest, added “MLM is known globally as a leader in central lab and specialty testing solutions and together we have an extraordinary synergy in terms of our collective focus on scientific excellence and customized services. We are looking forward to joining forces and establishing a fully integrated central lab under one harmonized global brand.”

Finally, MLM is very proud to announce that Thomas Wollman, SVP Finance at Syneos Health, has joined MLM’s Board of Directors as of July 7, 2020. With his more than 25 years of experience in the central laboratory and CRO market, including responsibility for Quintiles’ central lab operations, he will help the team to further develop MLM as one of the leading international central labs for clinical trials.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $2.2 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.6 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, medical device, information technology enabled businesses and alternate site care. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or http://www.gppfunds.com.

About MLM Medical Labs

MLM Medical Labs founded 1993 is a Central Laboratory dedicated exclusively to clinical trials. MLM offers a full range of laboratory services, including specialized biomarker testing, clinical chemistry, standard safety profiles, and analyses of drug compounds, metabolites and molecular diagnostic parameters. Internationally active in over 40 countries, including the U.S. and Eastern Europe, MLM is headquartered in Moenchengladbach, Germany (near Duesseldorf International Airport). MLM works 365 days a year in order to ensure valid, high-quality, results with a quick turnaround time. For more information, please visit https://www.mlm-labs.com/

Share article on social media or email:

Press Release News Wire Service